IO Biotech, Inc.
NASDAQ: IOBT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mai-Britt Zocca
- Employees
- 80
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2021
- Market cap
- $885.7K
- Website
- https://www.iobiotech.com
Loading IOBT…
Loading profile data…Frequently asked questions about IOBT
What does IO Biotech, Inc. (IOBT) do?
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and...
Where does IOBT trade?
IO Biotech, Inc. (IOBT) trades on the NASDAQ Global Select.
What sector is IOBT in?
IO Biotech, Inc. (IOBT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IO Biotech, Inc.?
Mai-Britt Zocca is the chief executive officer of IO Biotech, Inc. (IOBT).
Where is IO Biotech, Inc. headquartered?
IO Biotech, Inc. is headquartered in Denmark.
Does IOBT pay a dividend?
IO Biotech, Inc. (IOBT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IOBT go public?
IO Biotech, Inc. (IOBT) completed its initial public offering in 2021.